From USFDA
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, the generic version of Exjade1 Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, of Novartis Pharmaceuticals Corporation.According to IQVIATM sales data for the 12‐month period ending November 2019, the Exjade Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg market achieved annual sales of approximately $106.4 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
